Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Evaluation of saliva as a potential alternative sampling matrix for therapeutic drug monitoring of levofloxacin in MDR-TB patients.

Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, van der Werf TS, Shrestha B, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Feb 19. pii: AAC.02379-18. doi: 10.1128/AAC.02379-18. [Epub ahead of print]

PMID:
30782999
2.

Levofloxacin pharmacokinetics and pharmacodynamics and outcome in MDR-TB patients.

Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, van der Werf TS, Shrestha B, Alffenaar JC.

Eur Respir J. 2019 Jan 17. pii: 1802107. doi: 10.1183/13993003.02107-2018. [Epub ahead of print] No abstract available.

PMID:
30655280
3.

The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.

Pranger AD, van der Werf TS, Kosterink JGW, Alffenaar JWC.

Drugs. 2019 Feb;79(2):161-171. doi: 10.1007/s40265-018-1043-y. Review.

4.

Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data.

Daskapan A, Tran QTD, Cattaneo D, Gervasoni C, Resnati C, Stienstra Y, Bierman WFW, Kosterink JGW, van der Werf TS, Proost JH, Alffenaar JC, Touw DJ.

Ther Drug Monit. 2019 Feb;41(1):59-65. doi: 10.1097/FTD.0000000000000576.

5.

Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

van Rijn SP, Zuur MA, Anthony R, Wilffert B, van Altena R, Akkerman OW, de Lange WCM, van der Werf TS, Kosterink JGW, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01489-18. doi: 10.1128/AAC.01489-18. Print 2019 Feb.

PMID:
30455232
6.

Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice.

Gareb B, Dijkstra G, Kosterink JGW, Frijlink HW.

Int J Pharm. 2019 Jan 10;554:366-375. doi: 10.1016/j.ijpharm.2018.11.019. Epub 2018 Nov 8.

PMID:
30414898
7.

A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs.

Daskapan A, Idrus LR, Postma MJ, Wilffert B, Kosterink JGW, Stienstra Y, Touw DJ, Andersen AB, Bekker A, Denti P, Hemanth Kumar AK, Jeremiah K, Kwara A, McIlleron H, Meintjes G, van Oosterhout JJ, Ramachandran G, Rockwood N, Wilkinson RJ, van der Werf TS, Alffenaar JC.

Clin Pharmacokinet. 2018 Nov 8. doi: 10.1007/s40262-018-0716-8. [Epub ahead of print] Review.

8.

Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non-Ig scaffolds.

Warnders FJ, Lub-de Hooge MN, de Vries EGE, Kosterink JGW.

Med Res Rev. 2018 Sep;38(6):1837-1873. doi: 10.1002/med.21498. Epub 2018 Apr 10. Review.

PMID:
29635825
9.

Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.

Zuur MA, Ghimire S, Bolhuis MS, Wessels AMA, van Altena R, de Lange WCM, Kosterink JGW, Touw DJ, van der Werf TS, Akkerman OW, Alffenaar JWC.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02250-17. doi: 10.1128/AAC.02250-17. Print 2018 May.

10.

In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin.

Dijkstra JA, van der Laan T, Akkerman OW, Bolhuis MS, de Lange WCM, Kosterink JGW, van der Werf TS, Alffenaar JWC, van Soolingen D.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01724-17. doi: 10.1128/AAC.01724-17. Print 2018 Mar.

11.

Risk factors contributing to a low darunavir plasma concentration.

Daskapan A, Stienstra Y, Kosterink JGW, Bierman WFW, van der Werf TS, Touw DJ, Alffenaar JC.

Br J Clin Pharmacol. 2018 Mar;84(3):456-461. doi: 10.1111/bcp.13464. Epub 2017 Dec 7.

12.

Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine.

Geers LM, Cohen D, Wehkamp LM, van Hateren K, Koster RA, Fedorenko OY, Semke AV, Bokhan N, Ivanova SA, Kosterink JGW, Loonen AJM, Touw DJ.

J Clin Psychiatry. 2017 Nov/Dec;78(9):e1211-e1218. doi: 10.4088/JCP.16m11164.

PMID:
29068609
13.

Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.

Boonstra JM, van der Elst KC, Veringa A, Jongedijk EM, Brüggemann RJ, Koster RA, Kampinga GA, Kosterink JG, van der Werf TS, Zijlstra JG, Touw DJ, Alffenaar JWC.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01398-17. doi: 10.1128/AAC.01398-17. Print 2017 Dec.

14.

Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting.

Daskapan A, Dijkema D, de Weerd DA, Bierman WFW, Kosterink JGW, van der Werf TS, Alffenaar JC, Stienstra Y.

Br J Clin Pharmacol. 2017 Oct;83(10):2325-2329. doi: 10.1111/bcp.13366. Epub 2017 Aug 1.

15.

Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.

Van't Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K, van der Laan T, Kosterink JGW, van der Werf TS, van Soolingen D, van den Hof S, Skrahina A, Alffenaar JC.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00343-17. doi: 10.1128/AAC.00343-17. Print 2017 Aug.

16.

Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study.

Aardema H, Nannan Panday P, Wessels M, van Hateren K, Dieperink W, Kosterink JGW, Alffenaar JW, Zijlstra JG.

Int J Antimicrob Agents. 2017 Jul;50(1):68-73. doi: 10.1016/j.ijantimicag.2017.02.020. Epub 2017 May 10.

PMID:
28501674
17.

Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.

Kamp J, Bolhuis MS, Tiberi S, Akkerman OW, Centis R, de Lange WC, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JC.

Int J Antimicrob Agents. 2017 Jun;49(6):688-694. doi: 10.1016/j.ijantimicag.2017.01.017. Epub 2017 Apr 4.

PMID:
28389352
18.

Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of 89Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging.

Warnders FJ, Terwisscha van Scheltinga AGT, Knuehl C, van Roy M, de Vries EFJ, Kosterink JGW, de Vries EGE, Lub-de Hooge MN.

J Nucl Med. 2017 Aug;58(8):1210-1215. doi: 10.2967/jnumed.116.181586. Epub 2017 Mar 30.

19.

Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.

Van der Paardt AL, Akkerman OW, Gualano G, Palmieri F, Davies Forsman L, Aleksa A, Tiberi S, de Lange WC, Bolhuis MS, Skrahina A, van Soolingen D, Kosterink JG, Migliori GB, van der Werf TS, Alffenaar JC.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601612. doi: 10.1183/13993003.01612-2016. Print 2017 Mar. No abstract available.

20.

Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.

van Rijn SP, Zuur MA, van Altena R, Akkerman OW, Proost JH, de Lange WC, Kerstjens HA, Touw DJ, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01783-16. doi: 10.1128/AAC.01783-16. Print 2017 Apr.

21.

Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.

van Altena R, Dijkstra JA, van der Meer ME, Borjas Howard JF, Kosterink JG, van Soolingen D, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01400-16. doi: 10.1128/AAC.01400-16. Print 2017 Mar.

22.

Bioavailability of voriconazole in hospitalised patients.

Veringa A, Geling S, Span LF, Vermeulen KM, Zijlstra JG, van der Werf TS, Kosterink JG, Alffenaar JC.

Int J Antimicrob Agents. 2017 Feb;49(2):243-246. doi: 10.1016/j.ijantimicag.2016.10.010. Epub 2016 Nov 23.

PMID:
28012684
23.

The effect of inflammation on voriconazole trough concentrations in children.

Ter Avest M, Veringa A, van den Heuvel ER, Kosterink JG, Schölvinck EH, Tissing WJ, Alffenaar JC.

Br J Clin Pharmacol. 2017 Mar;83(3):678-680. doi: 10.1111/bcp.13151. Epub 2016 Nov 9. No abstract available.

24.

Low Caspofungin Exposure in Patients in Intensive Care Units.

van der Elst KC, Veringa A, Zijlstra JG, Beishuizen A, Klont R, Brummelhuis-Visser P, Uges DR, Touw DJ, Kosterink JG, van der Werf TS, Alffenaar JC.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01582-16. doi: 10.1128/AAC.01582-16. Print 2017 Feb.

25.

Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting.

Van't Boveneind-Vrubleuskaya N, Daskapan A, Kosterink JG, van der Werf TS, van den Hof S, Alffenaar JC.

PLoS One. 2016 Nov 10;11(11):e0166030. doi: 10.1371/journal.pone.0166030. eCollection 2016.

26.

Voriconazole metabolism is influenced by severe inflammation: a prospective study.

Veringa A, Ter Avest M, Span LF, van den Heuvel ER, Touw DJ, Zijlstra JG, Kosterink JG, van der Werf TS, Alffenaar JC.

J Antimicrob Chemother. 2017 Jan;72(1):261-267. Epub 2016 Sep 6.

PMID:
27601292
27.

Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.

Sturkenboom MG, Akkerman OW, van Altena R, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JC.

Eur Respir J. 2016 Oct;48(4):1237-1239. doi: 10.1183/13993003.00986-2016. Epub 2016 Aug 4. No abstract available.

28.

Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.

Ghimire S, Van't Boveneind-Vrubleuskaya N, Akkerman OW, de Lange WC, van Soolingen D, Kosterink JG, van der Werf TS, Wilffert B, Touw DJ, Alffenaar JW.

J Antimicrob Chemother. 2016 Oct;71(10):2691-703. doi: 10.1093/jac/dkw164. Epub 2016 May 26. Review.

PMID:
27231277
29.

Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use.

Ter Weele EJ, Terwisscha van Scheltinga AG, Linssen MD, Nagengast WB, Lindner I, Jorritsma-Smit A, de Vries EG, Kosterink JG, Lub-de Hooge MN.

Eur J Pharm Biopharm. 2016 Jul;104:226-34. doi: 10.1016/j.ejpb.2016.05.008. Epub 2016 May 12.

PMID:
27179587
30.

Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.

Alsaad N, Dijkstra JA, Akkerman OW, de Lange WC, van Soolingen D, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3942-7. doi: 10.1128/AAC.02175-15. Print 2016 Jul.

31.

Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?

Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JW.

Eur Respir J. 2016 Apr;47(4):1288-90. doi: 10.1183/13993003.02185-2015. No abstract available.

32.

Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease.

Gareb B, Eissens AC, Kosterink JGW, Frijlink HW.

Eur J Pharm Biopharm. 2016 Jun;103:32-42. doi: 10.1016/j.ejpb.2016.03.018. Epub 2016 Mar 19.

PMID:
27000751
33.

Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study.

Maurer JM, Hofman S, Schellekens RC, Tonnis WF, Dubois AO, Woerdenbag HJ, Hinrichs WL, Kosterink JG, Frijlink HW.

Int J Pharm. 2016 May 30;505(1-2):175-86. doi: 10.1016/j.ijpharm.2016.03.027. Epub 2016 Mar 17.

PMID:
26997425
34.

Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.

Encalada Ventura MA, van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2727-31. doi: 10.1128/AAC.02830-15. Print 2016 May.

35.

Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM.

Warnders FJ, Waaijer SJ, Pool M, Lub-de Hooge MN, Friedrich M, Terwisscha van Scheltinga AG, Deegen P, Stienen SK, Pieslor PC, Cheung HK, Kosterink JG, de Vries EG.

J Nucl Med. 2016 May;57(5):812-7. doi: 10.2967/jnumed.115.168153. Epub 2016 Feb 4.

36.

Voriconazole Therapeutic Drug Monitoring Practices in Intensive Care.

van Wanrooy MJ, Rodgers MG, Span LF, Zijlstra JG, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Ther Drug Monit. 2016 Jun;38(3):313-8. doi: 10.1097/FTD.0000000000000284.

PMID:
26845112
37.

End TB with precision treatment!

van der Burgt EP, Sturkenboom MG, Bolhuis MS, Akkerman OW, Kosterink JG, de Lange WC, Cobelens FG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Feb;47(2):680-2. doi: 10.1183/13993003.01285-2015. No abstract available.

38.

Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.

van Rijn SP, van Altena R, Akkerman OW, van Soolingen D, van der Laan T, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Apr;47(4):1229-34. doi: 10.1183/13993003.01654-2015. Epub 2016 Jan 7.

39.

Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.

Saktiawati AM, Sturkenboom MG, Stienstra Y, Subronto YW, Sumardi, Kosterink JG, van der Werf TS, Alffenaar JW.

J Antimicrob Chemother. 2016 Mar;71(3):703-10. doi: 10.1093/jac/dkv394. Epub 2015 Dec 11.

PMID:
26661397
40.

Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease.

van der Elst KC, Brouwers CH, van den Heuvel ER, van Wanrooy MJ, Uges DR, van der Werf TS, Kosterink JG, Span LF, Alffenaar JW.

Ther Drug Monit. 2015 Dec;37(6):766-71. doi: 10.1097/FTD.0000000000000235.

PMID:
26565789
41.

Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.

ter Weele EJ, Terwisscha van Scheltinga AG, Kosterink JG, Pot L, Vedelaar SR, Lamberts LE, Williams SP, Lub-de Hooge MN, de Vries EG.

Oncotarget. 2015 Dec 8;6(39):42081-90. doi: 10.18632/oncotarget.5877.

42.

Letter: infliximab therapy for patients with inflammatory bowel disease--some unanswered questions. Authors' reply.

Buurman DJ, Maurer JM, Keizer RJ, Kosterink JG, Dijkstra G.

Aliment Pharmacol Ther. 2015 Nov;42(9):1134. doi: 10.1111/apt.13396. No abstract available.

43.

The relation of the number of hydrogen-bond acceptors with recoveries of immunosuppressants in DBS analysis.

Koster RA, Alffenaar JW, Botma R, Greijdanus B, Uges DR, Kosterink JG, Touw DJ.

Bioanalysis. 2015;7(14):1717-22. doi: 10.4155/bio.15.94.

PMID:
26270779
44.

Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis.

Dijkstra JA, van Altena R, Akkerman OW, de Lange WC, Proost JH, van der Werf TS, Kosterink JG, Alffenaar JW.

Int J Antimicrob Agents. 2015 Sep;46(3):332-7. doi: 10.1016/j.ijantimicag.2015.06.008. Epub 2015 Jul 15.

PMID:
26228464
45.

Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets.

Maurer JM, Schellekens RC, van Rieke HM, Wanke C, Iordanov V, Stellaard F, Wutzke KD, Dijkstra G, van der Zee M, Woerdenbag HJ, Frijlink HW, Kosterink JG.

PLoS One. 2015 Jul 15;10(7):e0129076. doi: 10.1371/journal.pone.0129076. eCollection 2015.

46.

Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study.

Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JW.

Eur Respir J. 2015 Oct;46(4):1205-7. doi: 10.1183/13993003.00606-2015. Epub 2015 Jul 9. No abstract available.

47.

Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.

Buurman DJ, Maurer JM, Keizer RJ, Kosterink JG, Dijkstra G.

Aliment Pharmacol Ther. 2015 Sep;42(5):529-39. doi: 10.1111/apt.13299. Epub 2015 Jun 26.

48.

Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.

Sturkenboom MG, Mulder LW, de Jager A, van Altena R, Aarnoutse RE, de Lange WC, Proost JH, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2015 Aug;59(8):4907-13. doi: 10.1128/AAC.00756-15. Epub 2015 Jun 8.

49.

The performance of five different dried blood spot cards for the analysis of six immunosuppressants.

Koster RA, Botma R, Greijdanus B, Uges DR, Kosterink JG, Touw DJ, Alffenaar JW.

Bioanalysis. 2015;7(10):1225-35. doi: 10.4155/bio.15.63.

PMID:
26045003
50.

Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis.

van der Paardt AF, Wilffert B, Akkerman OW, de Lange WC, van Soolingen D, Sinha B, van der Werf TS, Kosterink JG, Alffenaar JW.

Eur Respir J. 2015 Aug;46(2):444-55. doi: 10.1183/09031936.00147014. Epub 2015 May 28. Review.

Supplemental Content

Loading ...
Support Center